O-(2-[18F]fluoroethyl)-L-tyrosine (FET) pet vs. stereotactic biopsy in glioma-patients after multimodal therapy: impact on treatment decision

Objective: O-(2-[18F]fluoroethyl)-L-tyrosine (FET) PET has been reported to offer a promising diagnostic tool when differentiation between tumor- and therapy-associated contrast enhancement on MRI in patients with gliomas undergoing multimodal treatment is difficult. However, the impact of FET-PET findings on treatment decision remains uncertain and has yet to be evaluated. Methods: In a prospective study, a FET-PET investigation was performed in all glioma patients after multimodal therapy with the neuroradiological diagnosis (based on MRI) of a tumor recurrence between December 2003 and January 2005. Criteria…